Evolus, Inc.
EOLS Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$7.01
KIRA · Stoqly’s AI analyst, in plain words
- Evolus, Inc. had $297M of revenue in fiscal 2025, up 11.6% on the year before. Over five years, revenue changed +39.4% a year on average.
- Its operating margin was −11.0%, up 1.9 pts: of every 100 in sales, about −11 is left after running the business.
- Evolus, Inc. lost $51.6M in fiscal 2025.
- Free cash flow was −$45.7M in fiscal 2025, −15.4% of revenue.
- Evolus, Inc. owes $92.3M more than it holds in cash.
Market cap
$462M
P/E
—
Revenue
$297M
Net income
−$51.6M
Free cash flow
−$45.7M
Operating margin
−11.0%
Evolus, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+11.6%
Yes. Sales grew 11.6% last year.
Does it make a profit?
−17.4%
No. It lost money last year.
Does profit turn into cash?
−15.4%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 9
Weak. It passes 2 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Evolus, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 3, 2026
- Legal name
- Evolus, Inc.
- CIK
- 0001570562
Evolus, Inc. · EOLS
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $99.7M | $149M | $202M | $266M | $297M |
| Revenue growth | 76.3% | 49.1% | 36.0% | 31.8% | 11.6% |
| Gross margin | 56.3% | 60.4% | 68.1% | 68.5% | 66.3% |
| Operating margin | −44.6% | −44.0% | −24.4% | −12.9% | −11.0% |
| Net income | −$46.8M | −$74.4M | −$61.7M | −$50.4M | −$51.6M |
| Net margin | −47.0% | −50.1% | −30.5% | −18.9% | −17.4% |
| Diluted EPS | −$0.94 | −$1.33 | −$1.08 | −$0.81 | −$0.80 |
| Cash | |||||
| Cash from operations | −$33.4M | −$84.9M | −$34.0M | −$18.0M | −$42.3M |
| Capital expenditure | $0.4M | $1.6M | $0.5M | $1.5M | $3.4M |
| Free cash flow | −$33.8M | −$86.5M | −$34.5M | −$19.5M | −$45.7M |
| FCF margin | −33.9% | −58.2% | −17.1% | −7.3% | −15.4% |
| Share count change | 47.5% | 12.6% | 1.5% | 9.0% | 4.0% |
| Debt and strength | |||||
| Cash and short-term investments | $146M | $53.9M | $62.8M | $87.0M | $53.8M |
| Debt incl. finance leases | $71.2M | $71.9M | $120M | $122M | $146M |
| Shareholders' equity | $81.9M | $18.5M | −$20.7M | $5.5M | −$23.1M |
| Current ratio | 3.1x | 2.2x | 2.3x | 2.4x | 1.9x |
| Interest coverage | −31.8x | −7.2x | −3.6x | −1.8x | −1.7x |
| Returns and quality | |||||
| Return on capital | −512.7% | −141.6% | −105.6% | −67.8% | −37.3% |
| Return on equity | −1,049.8% | −148.3% | — | — | — |
| Return on tangible equity | −466.1% | — | — | — | — |
| Piotroski F-score | 4 | 2 | 5 | 6 | 2 |
| Altman Z'' | −2.9 | −9.5 | −9.3 | −7.0 | −8.6 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$1.8M
2 insiders
Of sales under plans
48%
$0.9M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Evolus, Inc. · EOLS
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $7.01 a share, the company is worth $462M.
Source: SEC EDGAR XBRL filings (CIK 0001570562). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.